Conversely, prospective clinical observations reported traditional NSAIDs or selective cyclooxygenase 2 (COX2) inhibitors did not slow down the cognitive decline associated with mild-to-moderate AD [113–115]. This evidence concerns the gene PTGS2 and Alzheimer disease.